leadf
logo-loader
viewXPhyto Therapeutics Corp.

XPhyto Therapeutics updates on progress of coronavirus screening test

The bioscience firm said its exclusive diagnostic partner, 3a-Diagnostics, has taken possession of COVID-19 RNA for its second round of proof-of-concept prototype testing, with results from the evaluation process expected within 30 days

XPhyto Therapeutics Corp. - XPhyto Therapeutics updates on progress of coronavirus screening test
The test is designed to detect COVID-19 viral RNA from patient saliva samples and nasal and throat swabs

XPhyto Therapeutics Corp (CSE:XPHY) (OTCQB:XPHYF) (FRA:4XT) has released an update on the development of its rapid coronavirus (COVID-19) screening test.

The bioscience company said its exclusive diagnostic partner, 3a-Diagnostics GmbH, is developing a rapid, disposable, point-of-care lateral flow screening test to detect COVID-19 viral RNA from patient saliva samples and nasal and throat swabs.

READ: XPhyto Therapeutics rapidly advances its drug delivery system for Parkinson's skin patches

3a has now taken possession of COVID-19 RNA isolated from live viable virus for its second round of proof-of-concept prototype testing, XPhyto said, adding that the evaluation process is currently underway and results are expected within 30 days.

The group said that pending successful evaluation results, it will proceed to advanced prototype production and usability testing scheduled for the fourth quarter of 2020, adding that test development and optimization is continuing to proceed on an expedited basis at 3a's research lab and in collaboration with third party contractors and academic partners in Germany.

"In general, the scientific understanding of the COVID-19 virus and an active infection is rapidly evolving. It's a dynamic situation but XPhyto is bolstered by the emerging scientific literature that supports the use of saliva tests over nasopharyngeal swabs and molecular (RNA) tests over other forms of detection, which may be susceptible to false negatives," XPhyto chief executive Hugh Rogers said in a statement.

XPhyto is a diversified bioscience company with strategic assets and investments in the field of next-generation drug delivery and rapid pathogen screening systems as well as medical cannabis opportunities focused on European markets. The company focuses on clinical programs for the transdermal and dissolvable oral delivery of conventional and cannabis-based narcotics for neurological applications, as well as rapid dissolvable oral biosensor and lateral flow assay-based screening tests for dental health applications and high-risk pandemic threats such as COVID-19, swine flu and avian flu.

Contact the author at calum@proactiveinvestors.com

Follow him on Twitter @Cal_Proac

Quick facts: XPhyto Therapeutics Corp.

Price: 2.08 CAD

CSE:XPHY
Market: CSE
Market Cap: $120.66 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of XPhyto Therapeutics Corp. named herein, including the promotion by the Company of XPhyto Therapeutics Corp. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

XPhyto Therapeutics subsidiary Vektor Pharma develops oral disintegrating...

XPhyto Therapeutics Corp (CSE:XPHY) (OTCQB:XPHYF) (FRA:4XT) CEO Hugh Rogers tells Proactive the group's German subsidiary Vektor Pharma TF GmbH has developed an oral disintegrating film (ODF) drug delivery mechanism for a major European generic drug company. Rogers says during the third...

1 day, 1 hour ago

2 min read